Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

Livingstone, E; Gogas c , H.; Kandolf-Sekulović, Lidija O.; ...; Mijušković, Željko P.; ...; (broj, koautora 24)

Results

eNauka > Rezultati > Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial

Naziv:	Early switch from run-in treatment with vemurafenib plus cobimetinib to atezolizumab after 3 months leads to rapid loss of tumour control in patients with advanced BRAFV600-positive melanoma: The ImmunoCobiVem phase 2 randomised trial
Autori :	Livingstone, E; Gogas c , H.; Kandolf-Sekulović, Lidija O.; ...; Mijušković, Željko P. ; ...; (broj, koautora 24)
Godina:	2023
Publikacija:	EUROPEAN JOURNAL OF CANCER
ISSN:	0959-8049 e1879-0852 European Journal of Cancer / EJC Pretraži identifikator
Izdavač:	Oxford : Elsevier Science Ltd
Tip rezultata:	Naučni članak
Kolacija:	vol. 190 br. (Article 112941) str. 1-13
DOI:	10.1016/j.ejca.2023.112941
WoS-ID:	001048101900001
Scopus-ID:	2-s2.0-85165712411
URI:	https://enauka.gov.rs/handle/123456789/802993
URL:	https://pdf.sciencedirectassets.com/271325/1-s2.0-S0959804923X00112/1-s2.0-S0959804923002903/main.pdf?X-Amz-Security-Token=IQoJb3JpZ2luX2VjENv%2F%2F%2F%2F%2F%2F%2F%2F%2F%2FwEaCXVzLWVhc3QtMSJIMEYCIQCBJlbUzZQ5BXrkZt9GPivlDnNGWHQ0mtaCgA1yiRuPxQIhAMKd4DsylKHTO7GzQwMrzO9vEaraDseNI6QUZs7NZLA1KrIFCHQQBRoMMDU5MDAzNTQ2ODY1IgykOYrhEaCdM2b9lzQqjwVepc3ZcMKe9%2BLEXDh0pEKWwAhVQSPhfJzTSIf5NpOM51gJJpl8Ei9mBStb5vHY%2BRd8lYg5Bxgd17Eq%2FDNsHbPAJ7mEWAyiWkAOs%2FSEWvtswQS4jpo8su9LeJYDQTK0Pjd8V6PiSX8xldJXawptuvoeMFgYOU7RJSunQtWdeWOcA24KBSo%2BMLNY7WsJ%2B4wC0sAuAi6xNNttGgDJbjRpN3etAKIZmLpNB5Iz5HC1MInOz8DF2QnxgB%2BEmgUWRWw13pWpIB8oQq7ivSFTZd4LC7xztUU%2BIQ0Zq4zBXhqDrx26k1V9Q5CtGUVyQOwC5AyFR1Ee2IJUpo5JlDzTfoC3vwBYBXmxSCY8vQlUBY4oDuLzM93ih5yq%2BigpRsdghUF%2B8T21j8Z3CzI4R5vn1ag69aQHUaB%2BVrmNTN6b%2B29ISdnzy%2B7zK1ZrXsDOVPxrM4%2FKnbBf67qVVowwnRNiCBlBRJgP9190WCxFNBkpWZbAZfZj83TUjz13E6OrZc32SzuASJxlRwa%2BN6XdbUYb0tpdg1jepxWoJETGIwFwvtViK8ZgXJxSgOR8RlDygntWG75K5PiM0QQsfnwUAtxxiDT0f%2ByXvOVqADbKprDePGuWBer9Y7vW2Qoug8IClmXtHkg5OMdvUsKhMeve1wLFP%2BRC1AWbf2oORpXU416%2BaewKMgEACSSFLr%2FAUePW9AEmyfc01LTHp7hqUtXyPE9Z9Fu2VsaTIE22f8YVOJuOC7Mhq9DgmCHLj793KRG6AEr3xrkLhMGH3DRsbz7ss7PhPE5f6S9PGtvlEXbnegA3V%2B0FBFUGlzzq2sJNrM5T31CkItNcgtVqOKbpOnckTF%2B06PTLIq9iOuYBAP2oXOoXbaQxdCa8MLGd2qwGOrABaMGq3eDEsp5Nc1w9NF3Nsp%2FuwUuOSqIdjXJt8qUGlaLrChHYqDe2vroh7DhRuJL1QZ69%2Fg451m9Q%2F6O8FBxfT9ZsgPSZktHNNmYrs41A2V%2BNmzggScXjy1KG9taDpd4oJ3UPQOIhJ07FsGMb0dQJ0gT%2BI5K1%2FoyQNEMoLb%2FQaTwYoOxEJIiWOICSKiQqR%2FRKzLls01wbXAlsWHy1tEfz24bIT7UM72YUxPYCdN6br1A%3D&X-Amz-Algorithm=AWS4-HMAC-SHA256&X-Amz-Date=20240104T112209Z&X-Amz-SignedHeaders=host&X-Amz-Expires=300&X-Amz-Credential=ASIAQ3PHCVTY43IPVLAH%2F20240104%2Fus-east-1%2Fs3%2Faws4_request&X-Amz-Signature=fce4155f2b2e77d960c87b7a4ff5b3b818260b2d218557f273dd6fb89d9639eb&hash=9d7c163630ba2b7d89ec26df505be1573aecc1fbccd9c6444c810b8c9ce5cd9f&host=68042c943591013ac2b2430a89b270f6af2c76d8dfd086a07176afe7c76c2c61&pii=S0959804923002903&tid=spdf-edb39382-7ad9-4bac-baad-f0afb635b306&sid=06c40f9e2ae67347b09939f214d00bf60a8agxrqb&type=client&tsoh=ZXpwcm94eS5uYi5yczoyMDU1&ua=1c1657525e5d5e0455&rr=84031a1f7a2f684d&cc=rs
Projekat:	F. Hoffmann-La Roche Ltd
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
Napomena:	22 koautora su zaposleni u institucijama u inostranstvu.
M-kategorija:	21aM21a - Vodeći međunarodni časopis kategorije M21a

8
SCOPUS^TM

7
WEB OF SCIENCE^TM

Altmetric

Dimensions

Unpaywall